Cryotherapy reduces accommodation

Article

Eyes treated with peripheral retinal cryotherapy lose accommodative amplitude after surgery, according to results of a study published in the January 2009 issue of the American Journal of Ophthalmology.

Eyes treated with peripheral retinal cryotherapy lose accommodative amplitude after surgery, according to results of a study published in the January 2009 issue of the American Journal of Ophthalmology.

Tsuyoshi Uno of Ideta Eye Hospital, Kumamoto, Japan and colleagues examined eyes with retinal lattice degeneration (n=96) treated with cryotherapy between December 2001 and September 2004, and measured pre- and postoperative accommodative amplitudes.

Overall, researchers did not note any significant differences between pre- and postoperative accommodative amplitudes, although patients aged 10–29 years demonstrated decreased accommodative amplitudes when measured one and three weeks after treatment. Within this age bracket, this decrease was more significant in younger subjects, although, for all patients, accommodative amplitude returned to pretreatment levels by week six. The researchers also noted an association between acute loss of accommodation and cryotherapy numbers.

The researchers concluded that, although short-term losses in accommodation are possible, and more common in patients aged 10–29 years, these losses resolved within six weeks.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.